ArticleInfection and drug resistance2024
Resilience and Beyond the Acute Phase Challenges: Case Series on Prolonged COVID-19 Infection in Immunocompromised Individuals.
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 infection is associated with an increased risk of severe illness and adverse outcomes in individuals with immunocompromising conditions. Immunocompromised patients may have difficulty with viral clearance, which can lead to persistent infection and potential relapses in viral replication. Case Presentation: Herein, we present four cases of persistent COVID-19 pneumonia in immunocompromised patients, including those with diffuse large B-cell lymphoma, polyarteritis nodosa, and end-stage renal disease post-kidney transplant. Three patients had previously received rituximab. Notably, all patients in this cohort demonstrated positive anti-receptor binding-domain immunoglobulin G (IgG) and negative anti-nucleocapsid IgG values. Conclusion: Persistent COVID-19 infection should be considered in the differential diagnosis of immunocompromised patients who exhibit ongoing symptoms or lack of improvement in chest X-ray findings following initial COVID-19 treatment. Early recognition, beyond the diagnosis of post-COVID organizing pneumonia, may significantly improve clinical outcomes with timely and appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.